SFTPB (rs11130866) and NR3C1 (rs41423247) gene variants as potential clinical biomarkers for personalized treatment strategy selection in patients with severe COVID-19 pneumonia

Pulmonary and renal long COVID at two-year revisit

“…Researchers speculate that SFTPB variants can affect the processing, secretion, and folding of SP-B in certain diseases. 31 SFTPB participates in immune regulation and plays an essential role in the defense and stability of the host airway. SFTPB deficiency is associated with various lung diseases, such as fatal respiratory failure, idiopathic pulmonary fibrosis, allergic pneumonia, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.…”

“…SFTPB deficiency is associated with various lung diseases, such as fatal respiratory failure, idiopathic pulmonary fibrosis, allergic pneumonia, chronic obstructive pulmonary disease, and acute respiratory distress syndrome. 31 , 32 Therefore, it can be inferred that SFTPB might be a potential biomarker for early and later monitoring of pulmonary long COVID. In contrast, persistent GGO lesions may turn into fibrous stripes, as observed in the newly emerged pulmonary long COVID cases in our cohort.…”

Novel Advancements in COVID-19 and Neuroscience

“…The purpose of this Special Issue resides in fostering further research to ultimately disentangle the pathophysiology underlying COVID-19. This may lead to the discovery of personalized treatments [54][55][56], which might reduce illness burden and increase well-being. To pursue such an aim, further research, as well as greater effort, is still needed.…”